Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis ; volume:22 ; number:1 ; day:12 ; month:3 ; year:2020 ; pages:1-2 ; date:12.2020
Breast cancer research ; 22, Heft 1 (12.3.2020), 1-2, 12.2020
- Creator
-
Zundelevich, Adi
Dadiani, Maya
Kahana-Edwin, Smadar
Itay, Amit
Sella, Tal
Gadot, Moran
Cesarkas, Karen
Farage-Barhom, Sarit
Saar, Efrat Glick
Eyal, Eran
Kol, Nitzan
Pavlovski, Anya
Balint-Lahat, Nora
Dick-Necula, Daniela
Barshack, Iris
Kaufman, Bella
Gal-Yam, Einav Nili
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-020-01265-y
- URN
-
urn:nbn:de:101:1-2020060406233007167960
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zundelevich, Adi
- Dadiani, Maya
- Kahana-Edwin, Smadar
- Itay, Amit
- Sella, Tal
- Gadot, Moran
- Cesarkas, Karen
- Farage-Barhom, Sarit
- Saar, Efrat Glick
- Eyal, Eran
- Kol, Nitzan
- Pavlovski, Anya
- Balint-Lahat, Nora
- Dick-Necula, Daniela
- Barshack, Iris
- Kaufman, Bella
- Gal-Yam, Einav Nili
- SpringerLink (Online service)
Other Objects (12)
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma
Deep learning-enabled breast cancer endocrine response determination from H&E staining based on ESR1 signaling activity
CARRYS
Locoregional tumor therapy
WORSE
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines
Locoregional Therapy for Cholangiocarcinoma
ESR1-Amplifikationen in humanen gynäkologischen Tumoren
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma
Deep learning-enabled breast cancer endocrine response determination from H&E staining based on ESR1 signaling activity
CARRYS
Locoregional tumor therapy
WORSE
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines
Locoregional Therapy for Cholangiocarcinoma
ESR1-Amplifikationen in humanen gynäkologischen Tumoren
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma
Deep learning-enabled breast cancer endocrine response determination from H&E staining based on ESR1 signaling activity
CARRYS
Locoregional tumor therapy
WORSE
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines
Locoregional Therapy for Cholangiocarcinoma